USMI and JCRI research teams develop treatment system for COVID and other respiratory infections and diseases


TAKOMA PARK, Maryland–(BUSINESS WIRE)–US Medical Innovations, LLC (USMI) and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) today announced that the United States Patent and Trademark Office has issued a notice of acceptance under the agreement of JCRI-ABTS US National Stage Application (Serial No. 17/284 762) entitled “SYSTEM FOR TREATMENT OF RESPIRATORY INFECTIONS AND CANCERS OF THE RESPIRATORY SYSTEM USING COLD ATMOSPHERE PLASMA”.

Cold atmospheric plasmas (CAC) are defined as specific forms of ionized gas composed of ions, photons, free electrons and complex chemical compositions. PACs produce various reactive oxygen species (ROS) and reactive nitrogen species (RNS) (i.e. singlet oxygen (1O2) ozone (O3), super anion (O2-), nitric oxide (-NO), nitric dioxide (-NO2), and the hydroxyl radical (-OH)) which have important biological and biomedical activities. CAPs have been shown to be effective in healing wounds, skin diseases, antifungal treatments and have also been reported to induce virus inactivation by several researchers around the world.

USMI and JCRI have developed a humidified electric reactive oxygen system (the Canady Helios™ Cold Plasma HERO™ System) that generates an ionized cold plasma mixed with air/O2 from oxygen sources such as hospital ventilators, CPAP (Continuous Positive Airway Pressure), BIPAP (Bilevel Positive Airway Pressure) or O2 face masks.

Jerome Canady, MD (CEO of USMI) said, “This is a very important addition to the company’s patent portfolio. Our team has already demonstrated that our Canady Helios Cold Plasma (CHCP) can be used to selectively fight breast cancer and many other cancers. Our preliminary research with the HERO system has shown it to be able to kill lung cancer cells in the laboratory, and we believe it has the potential to aid in the recovery of COVID-19 infected and affected patients. of lung cancer.

JCRI-ABTS also conducts research using the HERO system to deliver CAPs to treat cancer and other diseases of the abdomen and other body cavities via cannulas, laparoscopes and endoscopes.

The patent was filed with the USPTO on April 12, 2021. The US national stage application was based on International Application No. PCT/US2020/067503 filed on December 30, 2020. USMI and JCRI expect that the patent is granted by the end of the year.

About American Medical Innovations

USMI is a privately held US biomedical device company and a wholly owned subsidiary of US Patent Innovations, LLC. USMI focuses on plasma medicine. The company develops advanced electrosurgical devices and innovative robotic delivery systems for cancer eradication.


JCRI-ABTS is a state-of-the-art BSL 2 translational molecular research laboratory. Its objective is plasma oncotherapy (a new cancer treatment modality). JCRI-ABTS uses Canady Helios™ Cold Plasma to research and develop new methods to selectively treat and eradicate cancer.


Comments are closed.